Nedaplatin and Irinotecan in Patients with Large-cell Neuroendocrine Carcinoma of the Lung
- YOSHIYUKI KENMOTSU,
- FUMIHIRO OSHITA⇓,
- MAKIKO SUGIURA,
- SHUJI MURAKAMI,
- TETSURO KONDO,
- HARUHIRO SAITO and
- KOUZO YAMADA
- Correspondence to: Fumihiro Oshita, MD, Department of Thoracic Oncology, Kanagawa Cancer Center, Nakao 1-1-2, Asahi-ku, Yokohama 241-0815, Japan. Tel: +81453915761, Fax: +81453614692, e-mail: foshita{at}kcch.jp
Abstract
Background: No standard chemotherapy has been established for patients with large-cell neuroendocrine carcinoma (LCNEC). Patients and Methods: Patients with LCNEC of the lung were treated with nedaplatin (NP) at 50 mg/m2 and irinotecan at 50 mg/m2 on days 1 and 8 every four weeks for four cycles. Results: Data for 18 of the LCNEC patients were retrospectively analyzed. All patients were male, with a performance status 0 or 1, and the median age was 68 (range 58-80) years. Nine patients received adjuvant chemotherapy after undergoing complete surgical resection. Fourteen patients were able to receive four cycles of nedaplatin and irinotecan. Grade 4 leukopenia and neutropenia occurred in 5.6% and 16.7%, respectively. Four patients experienced grade 3 non-hematologic toxicities, such as diarrhea, enterocolitis, duodenal perforation and myocardial infarction. There were no treatment-related deaths. Two patients achieved complete response and four achieved partial response, and the median survival time was 12.3 months for the nine patients with advanced disease. Conclusion: Nedaplatin plus irinotecan is effective and safe for patients with LCNEC of the lung.
- Received February 20, 2012.
- Revision received March 12, 2012.
- Accepted March 13, 2012.
- Copyright© 2012 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved
